# ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement

Study · id `cardio:ct-nct05672836` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05672836](<https://clinicaltrials.gov/study/NCT05672836>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05672836

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1040 participants.

## Technical summary

Registry record NCT05672836. Randomized; quadruple masking; primary purpose treatment. Start 2024-12-18 (actual); primary completion 2028-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1040 participants (planned count; ClinicalTrials.gov record NCT05672836, source copy `cardio:ctgov-nct05672836-2026-06-29`, retrieved 2026-10-26)
- Started: 2024-12-18 (actual) (ClinicalTrials.gov record NCT05672836, source copy `cardio:ctgov-nct05672836-2026-06-29`, retrieved 2026-10-26)
- Primary completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT05672836, source copy `cardio:ctgov-nct05672836-2026-06-29`, retrieved 2026-10-26)
- Completion: 2029-04 (anticipated) (ClinicalTrials.gov record NCT05672836, source copy `cardio:ctgov-nct05672836-2026-06-29`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05672836, source copy `cardio:ctgov-nct05672836-2026-06-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05672836-2026-06-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement
- Acronym: ENAVO-TAVR
- Condition: Aortic Valve Stenosis
- Condition: Heart Failure
- Intervention (Drug): Enavogliflozin
- Intervention (Drug): Standard-of-Care
- Lead sponsor: Duk-Woo Park, MD
- Lead sponsor class: OTHER
- Collaborator: CardioVascular Research Foundation, Korea
- Collaborator class: OTHER
- Collaborator: Daewoong Pharmaceutical Co. LTD.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Duk-Woo Park, MD (`cardio:org-duk-woo-park-md`)
- Registry lists this organization as a collaborator: CardioVascular Research Foundation, Korea (`cardio:org-cardiovascular-research-foundation-korea`)
- Registry lists this organization as a collaborator: Daewoong Pharmaceutical Co. LTD. (`cardio:org-daewoong-pharmaceutical-co-ltd`)

## Provenance

Content hash: 26fc113f7dc346676098e8767a81515d25695900eb5340e4aaefa6bb9a2cae85
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
